Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

ObjectiveProviding the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Laura Rosiñol, Benjamin Hebraud, Albert Oriol, Anne-Laurène Colin, Rafael Ríos Tamayo, Cyrille Hulin, María Jesús Blanchard, Denis Caillot, Anna Sureda, Miguel Teodoro Hernández, Bertrand Arnulf, Maria-Victoria Mateos, Margaret Macro, Jesús San-Miguel, Karim Belhadj, Juan José Lahuerta, M. Brigid Garelik, Joan Bladé, Philippe Moreau
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Subjects:	multiple myeloma bortezomib lenalidomide dexamethasone thalidomide
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1197340/full